-
Mashup Score: 0Are we ready for long-acting HIV treatment for adolescents? - 1 month(s) ago
Adolescents with HIV have worse health outcomes along each step of the HIV care cascade worldwide compared with adults.1 Considerable socioeconomic, behavioural, and developmental differences between adolescents and adults contribute to this health inequity.2 Adolescents with HIV face multiple challenges in initiating and adhering to oral HIV treatment, including being able to independently access confidential health care, dual HIV and sexual and reproductive health stigma, poverty, violence, limited health literacy, risk-taking behaviour, mental health distress, and substance abuse.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 41The Lancet HIV, April 2024, Volume 11, Issue 4, Pages e199-e272 - 1 month(s) ago
Explore the current issue of The Lancet HIV, a monthly journal dedicated to publishing content that advocates for change in or illuminates HIV clinical practice
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 6Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study - 2 month(s) ago
Scaling up PrEP using HIV self-testing has similar health impacts, costs, and low risk of drug resistance as provider-administered rapid diagnostic tests. Policy makers should consider leveraging HIV self-testing to expand PrEP access among those at HIV risk.
Source: www.thelancet.comCategories: General Medicine News, HIV/AIDSTweet
-
Mashup Score: 116Retiring the term AIDS for more descriptive language - 2 month(s) ago
The term acquired immunodeficiency syndrome (AIDS) was coined to describe a condition marked by weakened cell-mediated immunity in the absence of a clear cause. Due to unfortunate messaging during the early days of the HIV epidemic, this term became loaded with stigma. After the discovery of HIV, the term AIDS became redundant, but its use has persisted and has come to embody negative connotations in the current landscape of the HIV epidemic. People commonly associate AIDS with a terminal illness.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 116Retiring the term AIDS for more descriptive language - 2 month(s) ago
The term acquired immunodeficiency syndrome (AIDS) was coined to describe a condition marked by weakened cell-mediated immunity in the absence of a clear cause. Due to unfortunate messaging during the early days of the HIV epidemic, this term became loaded with stigma. After the discovery of HIV, the term AIDS became redundant, but its use has persisted and has come to embody negative connotations in the current landscape of the HIV epidemic. People commonly associate AIDS with a terminal illness.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Lenacapavir plus two bNAbs: feasible, with some caveats - 2 month(s) ago
Antiretroviral therapy (ART) has reached very high levels of efficacy, tolerability, and convenience.1 Combining oral drugs in a single pill once daily is the current gold standard for ART. As HIV cure remains elusive, the simplification of therapy is desired for many people with HIV.2 We know that a combination of at least two drugs is needed: monotherapy, even with potent and high-genetic barrier drugs such as boosted protease inhibitors or dolutegravir, has led to an increased risk of virological failure, with potential for class resistance mutations, particularly in the case of dolutegravir.
Source: www.thelancet.comCategories: General Medicine News, HIV/AIDSTweet
-
Mashup Score: 0HIV and people who inject drugs: inequality until death - 2 month(s) ago
In The Lancet HIV, Adam Trickey and colleagues show that scale-up of antiretroviral therapy (ART) and HIV care in Europe and North America have led to substantial reductions over time in rates of most leading causes of death among people with HIV, especially AIDS-related deaths.1 Trickey and colleagues’ analyses interestingly highlighted that people who inject drugs are subjected to increased rates of substance use, suicide, accident-related mortality, and respiratory-related mortality, despite a decline in rates of all-cause mortality over time.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 17Adam Trickey on trends in causes of death among people with HIV in Europe and North America - The Lancet HIV in conversation with - 2 month(s) ago
Editor-in-Chief Peter Hayward is joined by Adam Trickey (University of Bristol, UK) to discuss a recent study looking at trends in causes of death among people with HIV in Europe and North America.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00272-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhiv
Source: www.buzzsprout.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0The role of HIV biology in defining virological failure - 2 month(s) ago
In this issue of The Lancet HIV, Graeme Moyle and colleagues1 report 48-week results from the proof-of-concept WISARD trial. In the trial, 140 people with HIV who were virologically suppressed on antiretroviral therapy (ART) and had Lys103Asn mutations in a past clinical genotype were randomly assigned to either switch to dolutegravir plus rilpivirine or to continue their current treatment. Confirmed virological failure, defined as two consecutive measurements of plasma HIV RNA concentrations of greater than 50 copies per mL at least 2 weeks apart, was reported in three (3%) of 95 participants in the dolutegravir plus rilpivirine group versus one (2%) of 45 participants in the control group.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 8
Virological suppression was maintained at week 48 in most participants with Lys103Asn mutations when they switched from standard regimens to dolutegravir plus rilpivirine. The results of this pilot study, if maintained when the week 96 data are reported, support conduct of a large, well-powered trial of dolutegravir plus rilpivirine.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
Read related comment here: https://t.co/5MopQUasxC